(EMN) Eastman Chemical - Ratings and Ratios
Copolyesters, Cellulosic Biopolymers, Intermediates, Additives, Fibers
EMN EPS (Earnings per Share)
EMN Revenue
Description: EMN Eastman Chemical
Eastman Chemical Company is a specialty materials company serving various markets globally, including transportation, personal care, and construction. Its diverse product portfolio includes amine derivatives, specialty coalescents, copolyesters, and cellulose acetate tow, catering to multiple end-markets. The company operates through four segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers.
From a business perspective, Eastman Chemical Companys revenue streams are diversified across various industries, reducing dependence on a single market. The companys presence in the United States, China, and international markets provides a significant geographic diversification benefit. Key Performance Indicators (KPIs) to monitor include revenue growth, segment-wise profitability, and return on invested capital (ROIC). With a market capitalization of approximately $9 billion, the companys size and scale enable it to invest in research and development, driving innovation in its product offerings.
Analyzing the companys financials, the price-to-earnings (P/E) ratio of 9.90 and forward P/E of 11.11 suggest a relatively attractive valuation. The return on equity (RoE) of 16.08% indicates a strong ability to generate profits from shareholder capital. Other important metrics to consider include the debt-to-equity ratio, interest coverage, and cash flow conversion to assess the companys financial health and ability to service its debt.
To further evaluate Eastman Chemical Companys prospects, it is essential to examine its competitive positioning, market share, and growth prospects in its respective segments. The companys ability to innovate and expand its product portfolio, as well as its cost structure and efficiency, will be crucial in driving future performance. Monitoring industry trends, regulatory developments, and macroeconomic factors will also be vital in understanding the companys growth opportunities and challenges.
EMN Stock Overview
| Market Cap in USD | 7,801m |
| Sub-Industry | Diversified Chemicals |
| IPO / Inception | 1993-10-10 |
EMN Stock Ratings
| Growth Rating | -44.5% |
| Fundamental | 58.4% |
| Dividend Rating | 67.4% |
| Return 12m vs S&P 500 | -45.1% |
| Analyst Rating | 4.15 of 5 |
EMN Dividends
| Dividend Yield 12m | 4.35% |
| Yield on Cost 5y | 4.69% |
| Annual Growth 5y | 4.07% |
| Payout Consistency | 98.3% |
| Payout Ratio | 43.5% |
EMN Growth Ratios
| Growth Correlation 3m | -64.3% |
| Growth Correlation 12m | -92% |
| Growth Correlation 5y | -21.5% |
| CAGR 5y | -1.51% |
| CAGR/Max DD 3y | -0.03 |
| CAGR/Mean DD 3y | -0.19 |
| Sharpe Ratio 12m | -1.07 |
| Alpha | 0.00 |
| Beta | 0.983 |
| Volatility | 46.94% |
| Current Volume | 1084.9k |
| Average Volume 20d | 1205.8k |
| Stop Loss | 63.3 (-4.1%) |
| Signal | 0.50 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (832.0m TTM) > 0 and > 6% of Revenue (6% = 557.0m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.60% (prev 12.05%; Δ 5.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.00b > Net Income 832.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.70b) to EBITDA (1.72b) ratio: 2.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (116.2m) change vs 12m ago -2.02% (target <= -2.0% for YES) |
| Gross Margin 24.31% (prev 22.75%; Δ 1.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.55% (prev 61.14%; Δ 0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.56 (EBITDA TTM 1.72b / Interest Expense TTM 218.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.52
| (A) 0.11 = (Total Current Assets 4.02b - Total Current Liabilities 2.39b) / Total Assets 15.22b |
| (B) 0.67 = Retained Earnings (Balance) 10.14b / Total Assets 15.22b |
| (C) 0.08 = EBIT TTM 1.21b / Avg Total Assets 15.08b |
| (D) 1.05 = Book Value of Equity 9.79b / Total Liabilities 9.31b |
| Total Rating: 4.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.38
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 3.27% = 1.64 |
| 3. FCF Margin 4.41% = 1.10 |
| 4. Debt/Equity 0.88 = 2.13 |
| 5. Debt/Ebitda 2.98 = -1.74 |
| 6. ROIC - WACC (= 3.24)% = 4.05 |
| 7. RoE 14.38% = 1.20 |
| 8. Rev. Trend -49.86% = -3.74 |
| 9. EPS Trend 34.62% = 1.73 |
What is the price of EMN shares?
Over the past week, the price has changed by -1.16%, over one month by +1.61%, over three months by -13.27% and over the past year by -34.78%.
Is Eastman Chemical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EMN is around 59.58 USD . This means that EMN is currently overvalued and has a potential downside of -9.71%.
Is EMN a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.4 | 15.7% |
| Analysts Target Price | 76.4 | 15.7% |
| ValueRay Target Price | 65.1 | -1.4% |
Last update: 2025-09-13 04:34
EMN Fundamental Data Overview
CCE Cash And Equivalents = 423.0m USD (last quarter)
P/E Trailing = 9.5541
P/E Forward = 9.9206
P/S = 0.84
P/B = 1.3369
P/EG = 3.3056
Beta = 1.269
Revenue TTM = 9.28b USD
EBIT TTM = 1.21b USD
EBITDA TTM = 1.72b USD
Long Term Debt = 4.78b USD (from longTermDebt, last quarter)
Short Term Debt = 344.0m USD (from shortTermDebt, last quarter)
Debt = 5.13b USD (Calculated: Short Term 344.0m + Long Term 4.78b)
Net Debt = 4.70b USD (from netDebt column, last quarter)
Enterprise Value = 12.50b USD (7.80b + Debt 5.13b - CCE 423.0m)
Interest Coverage Ratio = 5.56 (Ebit TTM 1.21b / Interest Expense TTM 218.0m)
FCF Yield = 3.27% (FCF TTM 409.0m / Enterprise Value 12.50b)
FCF Margin = 4.41% (FCF TTM 409.0m / Revenue TTM 9.28b)
Net Margin = 8.96% (Net Income TTM 832.0m / Revenue TTM 9.28b)
Gross Margin = 24.31% ((Revenue TTM 9.28b - Cost of Revenue TTM 7.03b) / Revenue TTM)
Tobins Q-Ratio = 1.28 (Enterprise Value 12.50b / Book Value Of Equity 9.79b)
Interest Expense / Debt = 1.09% (Interest Expense 56.0m / Debt 5.13b)
Taxrate = 15.77% (170.0m / 1.08b)
NOPAT = 1.02b (EBIT 1.21b * (1 - 15.77%))
Current Ratio = 1.68 (Total Current Assets 4.02b / Total Current Liabilities 2.39b)
Debt / Equity = 0.88 (Debt 5.13b / last Quarter total Stockholder Equity 5.83b)
Debt / EBITDA = 2.98 (Net Debt 4.70b / EBITDA 1.72b)
Debt / FCF = 12.53 (Debt 5.13b / FCF TTM 409.0m)
Total Stockholder Equity = 5.78b (last 4 quarters mean)
RoA = 5.47% (Net Income 832.0m, Total Assets 15.22b )
RoE = 14.38% (Net Income TTM 832.0m / Total Stockholder Equity 5.78b)
RoCE = 11.48% (Ebit 1.21b / (Equity 5.78b + L.T.Debt 4.78b))
RoIC = 9.43% (NOPAT 1.02b / Invested Capital 10.84b)
WACC = 6.18% (E(7.80b)/V(12.93b) * Re(9.64%)) + (D(5.13b)/V(12.93b) * Rd(1.09%) * (1-Tc(0.16)))
Shares Correlation 3-Years: -90.08 | Cagr: -0.46%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.40% ; FCFE base≈484.6m ; Y1≈538.1m ; Y5≈703.7m
Fair Price DCF = 80.66 (DCF Value 9.26b / Shares Outstanding 114.8m; 5y FCF grow 12.71% → 3.0% )
EPS Correlation: 34.62 | EPS CAGR: -8.62% | SUE: -1.48 | # QB: 0
Revenue Correlation: -49.86 | Revenue CAGR: -5.68% | SUE: N/A | # QB: None
Additional Sources for EMN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle